trovafloxacin 129), 9 clinafloxacin PD 127,391) 10 and levofloxacin, 11 have reached or come close to clinical investigation. The antibacterial activities of these five quinolones were determined together with that of the established leader compound, ciprofloxacin, against a broad spectrum of bacterial pathogens (87 species). The results allow assessment of the activity of the new compounds against different groups of pathogens.
Introduction
Quinolones established in the therapy of both nosocomial and community-acquired infections are relatively limited in their antibacterial activity against anaerobes, enterococci, staphylococci, glucose-non-fermenting Gram-negative rods 1 and recently also against Enterobacteriaceae (mainly Escherichia coli and Klebsiella pneumoniae ). [2] [3] [4] [5] Modifications of the quinolone structure focus mainly on enhancing activity against these organisms. In addition, compounds with pharmacokinetics allowing once-daily dosing are favoured.
Results
The MICs of ciprofloxacin for the reference strains E. coli ATCC 25922 (0.004-0.008 mg/L), P. aeruginosa ATCC 27853 (0.5-1 mg/L) and S. aureus ATCC 29213 (0.5 mg/L) were within the acceptable quality control ranges of the National Committee for Clinical Laboratory Standards. 12 The majority of Enterobacteriaceae had MIC 90 s of 1 mg/L of all six quinolones (Table) . Clinafloxacin was the most active compound against all species including strains with ciprofloxacin MICs of >1 mg/L; it was two to four times more active than ciprofloxacin, Bay 12-8039 or gatifloxacin and four to eight times more active than levofloxacin or trovafloxacin. Activity against glucose-nonfermenting Gram-negative rods varied between species. The most active compounds against individual species were: ciprofloxacin and clinafloxacin against Pseudomonas fluorescens and Pseudomonas putida (MIC 90 0.5-2 mg/L), clinafloxacin against P. aeruginosa and Alcaligenes xylosoxidans (MIC 90 For S. pneumoniae, Bay 12-8039 and trovafloxacin had the lowest MIC 90 s (0.25 mg/L), and ciprofloxacin and levofloxacin the highest MIC 90 s (2 mg/L). Susceptibility of nonpneumococcal streptococci was high for Bay 12-8039, trovafloxacin, clinafloxacin and gatifloxacin (MIC 90 s 0.13-0.5 mg/L) and lower for ciprofloxacin and levofloxacin (MIC 90 s 1-2 mg/L).
All the fastidious organisms included were highly susceptible to all six quinolones (MIC 90 s 0.004-0.06 mg/L), with clinafloxacin being the most active. 
Discussion
The quinolone compounds studied differ in their structures mainly at positions R 1 , R 7 and X 8 ( Figure) . 13 The data allow discussion of specific structure-activity relationships similar to the analysis of Domagala. 13 The enhanced activity of some of the new quinolones observed against Grampositive cocci in comparison with ciprofloxacin (four to eight times) was found to be restricted to structures that carry at position C 7 an azabicyclo (trovafloxacin, Bay 12-8039, MIC 90 s 0.06-0.25 mg/L), 3-amino-pyrrolidinyl (clinafloxacin, MIC 90 s 0.06-0.25 mg/L) or 3-methylpiperazinyl (gatifloxacin, MIC 90 s 0.13-0.5 mg/L) moiety, but not a 4-methyl-piperazinyl moiety (levofloxacin, MIC 90 s 0.25-1 mg/L). Activity against Enterobacteriaceae at a level similar to ciprofloxacin was observed only for compounds with a cyclopropyl group at position N 1 (Bay 12-8039, gatifloxacin, clinafloxacin). In contrast, trovafloxacin (2,4-difluorophenyl group) and levofloxacin (benzoxazine bridge between C 8 and N 1 ) were two to four times less active against these organisms. The methoxy group at position C 8 in both Bay 12-8039 and gatifloxacin appears not to have a noticeable effect on antibacterial potency and spectrum even against anaerobes, since quinolones without this substitution (e.g. trovafloxacin) show equal activity.
Major causative organisms of infections of the upper and influence the susceptibility to quinolones of the S. pneumoniae isolates included.
From the results of this study the quinolones investigated may be classified by their activity against specific groups of pathogens. Against Gram-positive cocci, the highest, and about equal, activity was found for Bay 12-8039, clinafloxacin and trovafloxacin, while clinafloxacin was the most active compound against Enterobacteriaceae. Against Pseudomonas spp. clinafloxacin was the only compound with activity comparable to that of ciprofloxacin. Clinafloxacin was most active against fastidious organisms, while anaerobes, H. pylori and C. jejuni had lowest, and about equal, MICs of Bay 12-8039, gatifloxacin, clinafloxacin and trovafloxacin. A major breakthrough in quinolone antibacterial activity, e.g. against P. aeruginosa and B. cepacia, may require the introduction of novel structural elements.
